Head and Neck Cancer Science Highlights
This session highlights five of the most clinically relevant abstracts within the Head and Neck Cancer track of the 2022 ASTRO Annual Meeting Scientific Program. These noteworthy scientific abstracts share important findings and feature cutting edge research from leaders in the field. The Discussant compares and contrasts the current data to help you digest the latest science; places the study into context; and describes how the study can be put into clinical practice, if recommended.
Highlighted Abstracts include –
- Screening for Extranodal Extension with Deep Learning: Evaluation in ECOG-ACRIN E3311, a Randomized De-escalation Trial for HPV-associated Oropharyngeal Carcinoma
- A Phase II Study of Volume and Dose De-intensification Following Transoral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma
- Genomic Adjusted Radiation Dose (GARD) Predicts Overall Survival and Outperforms AJCC 8th Edition in Prognostication of HPV-positive Oropharyngeal Squamous Cell Carcinoma
- Intra-treatment Tumor Apparent Diffusion Coefficient, a Quantitative Imaging Metric, is Associated with Neck Nodal Recurrence in De-escalated Treatment of HPV-positive Oropharyngeal Cancer (OPC)
- Long-term risk of carotid stenosis and cerebrovascular disease after radiation therapy for head and neck cancer
This activity is available from April 25, 2023, through 11:59 p.m. Eastern time on December 31, 2023.
This activity was originally recorded at ASTRO’s 2022 Annual Meeting.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists and radiation dosimetrists.
Upon completion of this activity, participants:
- Evaluate the potential benefits and challenges of implementing AI algorithms for clinical decision-making
- Describe a clinical trial approach to postoperative radiation dose and volume reduction for HPV-associated oropharynx cancer
- Evaluate the potential role of biologic models and radiologic parameters in tailoring RT de-intensification approaches to individual patients
- Integrate vascular health in survivorship care of patients treated with RT for H&N cancer
Discussant: Danielle Margalit, MD, MPH Dana-Farber/Brigham & Women's Cancer Center, Harvard Medical School
- No conflicts of interest to disclose
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the free member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until December 31, 2023, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.